Illumina shares fell 18.6% on 2026-10-30, after the genomics company's third-quarter revenue of $1.13 billion rose 4.2% year on year but missed Wall Street's forecasts, even as adjusted profit beat estimates and full-year guidance moved higher.
A revenue miss despite raised guidance
Illumina's 8-K, filed 2026-10-29, showed GAAP operating margin of 27.0% for the quarter and non-GAAP diluted earnings per share, excluding one-off tariff refunds, of $1.44. A report said that figure beat analysts' consensus by 6.1%, and that the new guidance's midpoint of $4.65 billion sat 0.6% above the consensus revenue estimate. Chief executive Jacob Thaysen cited strong clinical sequencing demand and additional NovaSeq X instrument placements in lifting guidance. Illumina raised its 2026 revenue guidance to $4.64-$4.66 billion from $4.60-$4.64 billion, and non-GAAP EPS guidance to $5.40-$5.45 from $5.30-$5.40.
Organic revenue growth, which strips out tariff refunds, acquisitions and currency, was 4.8% for the quarter; excluding Greater China, where Illumina remains on the country's unreliable-entities list, rest-of-world organic growth was 4.7%, with the company attributing a 0.1 percentage-point drag to China. A report said shares tumbled in after-hours trading specifically on the company's China revenue challenges.
The size of the drop
The decline is Illumina's largest move in this direction since 11 October 2016, equal to 5.7x the stock's typical daily swing of 3.3% over the past year, on trading volume 1.5x its 30-day average. Shares closed at $$235.99, down from Thursday's $$290.06 close.
The move dwarfed the wider market: the S&P 500 fell 1.8% the same session, and the median covered life-sciences-tools-and-services stock fell 3.9%, a gap that points to a company-specific reaction rather than a sector-wide retreat.
| Session move, 2026-10-30 | Illumina | Peer median (life sciences tools) | S&P 500 |
|---|---|---|---|
| Change | −18.6% | −3.9% | −1.8% |
Why the sell-off may be bigger than the earnings miss alone
The strongest alternative reading is that Thursday's numbers were a pretext for profit-taking rather than a verdict on the business. One report framed the slide as tariff confusion and "AI woes" eating into a prior "157% run-up" in the shares, tying the sell-off to a broader retreat in technology names after other large companies reported weak results overnight. A separate report grouped Illumina with Amazon and Intel as overnight earnings losers during a session when technology futures fell sharply. Under that reading, a stock that had climbed sharply over the prior year was primed to fall hard on any disappointment, even one offset by raised guidance.
What the revenue miss means for Illumina's model value
Growth affects that model more than margin does: five percentage points more growth would make the model value rise 33.2%, and five points less would make it fall 25.4%. A one-point higher discount rate would make the model value fall 15.0%. By contrast, the free cash flow margin's actual move over the past year, if it persisted, would make the model value fall by just −0.1%, and each additional point of lower margin would make it fall 4.1%. Thursday's quarter changed the growth picture more than the margin one. These are model values under stated assumptions, not a comparison with the share price.